Welcome to our dedicated page for Diamedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DiaMedica Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke. Form 8-K reports cover operating and financial results, business updates, clinical and regulatory disclosures, material agreements and executive leadership changes.
The company’s proxy materials describe shareholder meeting matters, board governance, executive compensation and equity award information. Other filings address capital-structure activity, including at-the-market common share sales arrangements, as well as Regulation FD disclosures and risk-language tied to DM199 development and regulatory interactions.
DiaMedica Therapeutics Inc. director Randall Michael Giuffre received a grant of stock options representing 40,412 Voting Common Shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments.
DiaMedica Therapeutics Inc. director Richard Kuntz reported a grant of stock options. He received options covering 40,412 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments, and following this grant he holds 40,412 derivative securities directly.
DiaMedica Therapeutics Inc. director Daniel J. O'Connor received a grant of stock options to acquire 40,412 voting common shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments. Following this grant, he holds options for 40,412 shares directly.
DiaMedica Therapeutics Inc. director Tanya Lewis received a grant of stock options as part of her compensation. She was awarded 40,412 stock options with a conversion or exercise price of $5.84 per share, giving her the right to buy Voting Common Shares at that price.
The options are scheduled to vest in four equal quarterly installments and will expire on June 1, 2036. Following this grant, she holds 40,412 derivative securities related to this award, indicating a routine, compensation-related acquisition rather than an open-market purchase or sale.
DiaMedica Therapeutics Inc. director Charles Pauling Semba received a new stock option grant. He was awarded options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share. These options are scheduled to vest in four equal quarterly installments and expire on June 1, 2036.
DiaMedica Therapeutics Inc. director James T. Parsons received a stock option grant reported on a Form 4. He was awarded options to purchase 51,189 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036.
The grant is classified as a compensation-related award, not an open-market purchase, and is held directly. According to the disclosure, the options are scheduled to vest in four substantially equal quarterly installments, meaning his ability to exercise them will phase in over time.
DiaMedica Therapeutics Inc. President & CEO Dietrich John Pauls received a grant of stock options covering 380,000 Voting Common Shares. The options have an exercise price of $5.84 per share and expire on June 1, 2036.
The award is compensation-related rather than an open-market trade. It is scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments. Following this grant, he holds 380,000 stock options directly.
DiaMedica Therapeutics Inc. reported that its CFO and Secretary, Kellen Scott, received a grant of stock options classified as a derivative security. The award covers 162,000 stock options, each giving the right to buy one voting common share at an exercise price of $5.84 per share.
The options were granted as compensation, not as an open-market purchase, and are held directly. They are scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments, and they expire on June 1, 2036.
DiaMedica Therapeutics Inc. reported that its Chief Medical Officer, Julie Krop, received a new stock option grant. The award covers 67,500 stock options with an exercise price of $5.84 per share and expires on June 1, 2036.
The options relate to 67,500 voting common shares and were granted at no upfront cost as a compensation award. According to the vesting terms, 25% of the options are scheduled to vest on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments thereafter.
DiaMedica Therapeutics Inc. reported results from its 2026 Annual General Meeting of Shareholders. All seven incumbent directors were re-elected, with most nominees receiving over 10 million votes in favor. Shareholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026.
On an advisory basis, shareholders approved the company’s executive compensation, with 9,928,381 votes for and 271,093 against. They also approved an amendment to the Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares.